Melanoma of unknown primary site: A 33-year experience at the Turin Melanoma Centre

Melanoma Research

Volumn 20, Issue 3, 2010, Pages 227-232

  Savoia, Paola ^a   Fava, Paolo ^a   Osella Abate, Simona ^a   Nardò, Tiziana ^a   Comessatti, Alessandra ^a   Quaglino, Pietro ^a   Bernengo, Maria Grazia ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Melanoma; Prognosis; Survival; Unknown primary

Indexed keywords

ANTINEOPLASTIC AGENT; MONOPHENOL MONOOXYGENASE; RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER CENTER; CANCER IMMUNOTHERAPY; CANCER STAGING; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; ITALY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SKIN METASTASIS; SKIN SURGERY; VISCERAL METASTASIS; VITILIGO; DISEASE COURSE; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; SKIN NEOPLASMS; TREATMENT OUTCOME; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; HUMANS; ITALY; MALE; MELANOMA; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; PROSPECTIVE STUDIES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 77952143058     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328333bc04     Document Type: Article

References (28)

1. Pack GT, Gerber DM, Scharnagel IM. End results in the treatment of malignant melanoma; a report of 1190 cases. Ann Surg 1952;136:905-911.
2. Das Gupta T, Bowden L, Berg JW. Malignant melanoma of unknown primary origin. Surg Gynecol Obstet 1963;117:341-345.
3. Giuliano AE, Moseley HS, Morton DL. Clinical aspects of unknown primary melanoma. Ann Surg 1980;191:98-104.
4. Anbari KK, Schuchter LM, Bucky LP, Mick R, Synnestvedt M, Guerry D 4th, et al. Melanoma of unknown primary site: presentation, treatment, and prognosis-a single institution study. University of Pennsylvania Pigmented Lesion Study Group. Cancer 1997;79:1816-1821.
5. Katz KA, Jonasch E, Hodi FS, Soiffer R, Kwitkiwski K, Sober AJ, et al. Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res 2005;15:77-82.
6. Cormier JN, Xing Y, Feng L, Huang X, Davidson L, Gershenwald JE, et al. Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer 2006;106:2012-2020.
7. Wong JH, Cagle LA, Morton DL. Surgical treatment of lymph nodes with metastatic melanoma from unknown primary site. Arch Surg 1987;122:1380-1383.
8. Norman J, Cruse CW, Wells KE, Saba HI, Reintgen DS. Metastatic melanoma with an unknown primary. Ann Plast Surg 1992;28:81-84.
9. Sclagenhauff B, Stroebel W, Ellwanger U, Meier F, Zimmermann C, Breuninger H, et al. Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: recommendation for initial staging examinations. Cancer 1997;80:60-65.
10. Chang P, Knapper WH. Metastatic melanoma of unknown primary. Cancer 1982;49:1106-1111.
11. Panagopulos E, Murray D. Metastatic malignant melanoma of unknown primary origin: a study of 30 cases. J Surg Oncol 1983;23:8-10.
12. Bernengo MG, Doveil GC, Lisa F, Pippione M, Aloi FG, Stuardi C, et al. Melanoma cutaneo nel Centro Melanoma di Torino. Giorn It Derm Vener 1986;121:311-326.
13. Bernengo MG, Quaglino P, Cappello N, Fierro MT, Doveil GC, Macripó G, et al. Time course and pattern of first relapse in stage I-II primary cutaneous melanoma: a multivariate analysis of disease-free survival in 3174 patients followed-up at the Turin Melanoma Centre from 1975 to 2004. G Ital Dermatol Venereol 2005;140:191-200.
14. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N. Prognostic factors analysis of 17600 melanoma patients: validation of the American Joint Committee On Cancer Melanoma Staging System. J Clin Oncol 2001;19:3622-3634.
15. Osella Abate S, Savoia P, Cambieri I, Salomone B, Quaglino P, Bernengo MG. Role of RT-PCR tyrosinase detection in the monitoring of patients with advanced metastatic melanoma. Melanoma Res 2000;10:545-555.
16. Lee CC, Faries MB, Wanek LA, Morton DL. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol 2008;26:535-541.
17. Paul E, Mullhofer R. Metastasizing malignant melanoma from unknown primary tumour. Hautartz 1990;41:432-437.
18. Velez A, Walsh D, Karakousis CP. Treatment of unknown primary melanoma. Cancer 1991;68:2579-2581.
19. Mocellin S, Zavagno G, Nitti D. The prognostic value of serum S100B in patients with cutaneous melanoma: a meta-analysis. Int J Cancer 2008;123:2370-2376.
20. Tarhini AA, Stuckert J, Lee S, Sander C, Kirkwood JM. Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol. 2009;27:38-44.
21. Oberholzer PA, Urosevic M, Steinert HC, Dummer R. Baseline staging of melanoma with unknown primary site: the value of serum S100 protein and positron emission tomography. Dermatology 2008;217:351-355.
22. Osella-Abate S, Savoia P, Quaglino P, Fierro MT, Leporati C, Ortoncelli M, et al. Tyrosinase expression in the peripheral blood of stage III melanoma patients is associated to a poor prognosis: a clinical follow-up study of 110 patients. Br J Cancer 2003;89:1457-1462.
23. Bottger D, Dowden RV, Kay PP. Complete spontaneous regression of cutaneous primary malignant melanoma. Plast Reconstr Surg 1992;89:548-553.
24. Shenoy BV, Fort L III, Benjamin SP. Malignant melanoma primary in lymph node: the case of missing link. Am J Surg Pathol 1987;11:140-146.
25. Kovacs SO. Vitiligo. J Am Acad Dermatol 1998;38:647-666.
26. Quaglino P, Marenco F, Osella-Abate S, Cappello N, Ortoncelli M, Salomone B, et al. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a singleinstitution hospital-based observational cohort study. Ann Oncol 2009:21 [E-pub July 21].
27. Boasberg PD, Hoon DS, Piro LD, Martin MA, Fujimoto A, Kristedja TS, et al. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol 2006;126:2658-2663.
28. Lenzi R, Hess KR, Abbruzzese MC, Raber MN, Ordoñez NG, Abbruzzese JL. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown primary carcinoma? J Clin Oncol 1997;15:2056-2066.